Laxmi Dental Q1 FY27 transcript: Revenue ₹747m, PAT ₹103m

Transcript uploaded after earnings call

Laxmi Dental has uploaded the transcript of its Q1 FY27 earnings conference call held on August 12, 2026, offering investors additional context on the quarter’s performance and priorities. The company said it has informed both BSE and NSE about the transcript’s availability on its investor relations page. The update follows the company’s announcement of audited financial results for the quarter ended June 30, 2026.

The transcript highlights management’s commentary on revenue growth, margin expansion, and the role of product mix in improving profitability. It also includes key operational discussion around its dental laboratory and aligner solutions businesses. For market participants, earnings call transcripts often serve as a reference point for understanding what drove results and how management describes near-term execution.

Q1 FY27 results: highest-ever quarterly revenue

Laxmi Dental reported consolidated revenue of INR 747.0 million in Q1 FY27, compared with INR 656.0 million in Q1 FY26. This translated into year-on-year growth of 13.9% and was described by management as the company’s highest ever quarterly revenue. In the earnings call, the company attributed the growth to broad-based performance across its dental laboratory and aligner solutions.

The transcript also points to improvement in profitability during the quarter. Management said the improvement was largely driven by a favorable product mix. Alongside revenue growth, the quarter showed expansion in margins at the operating and net levels.

Profitability improved as margins expanded

EBITDA for Q1 FY27 stood at INR 143.6 million, up from INR 119.1 million in Q1 FY26, representing 20.6% year-on-year growth. EBITDA margin improved to 19.2% in Q1 FY27 versus 18.2% in Q1 FY26, indicating a 100 basis point expansion.

Profit after tax (after share of profit or loss from JVs) rose to INR 103.2 million in Q1 FY27 from INR 83.3 million in Q1 FY26, up 23.8% year on year. PAT margin was reported at 13.8% in Q1 FY27, compared with 12.7% in Q1 FY26. The management commentary in the call linked this trend to a healthier mix and improved profitability.

Gross profit and gross margin trend

Gross profit climbed to INR 587.0 million in Q1 FY27, up 22.1% year on year. Gross margin improved to 78.6% in Q1 FY27, compared with 73.3% in Q1 FY26 and 70.5% in Q4 FY26, according to the figures cited alongside the results.

A gross margin level in the high-70% range, along with expanding EBITDA and PAT margins, points to improving operating leverage during the quarter. The transcript notes that the company saw a “healthy improvement in profitability,” with product mix highlighted as a key driver.

Other reported metrics: EBIT, PBT and EPS

The quarter’s EBIT was reported at INR 123.4 million, reflecting 22.7% year-on-year growth. EBIT margin stood at 16.5% in Q1 FY27 versus 15.3% in Q1 FY26. Profit before tax (PBT) was INR 120.4 million in Q1 FY27, up 25.5% year on year.

On earnings per share, basic EPS was reported at INR 1.87 in Q1 FY27 compared with INR 1.53 in Q1 FY26. Diluted EPS was INR 1.87 in Q1 FY27 versus INR 1.52 in Q1 FY26. The company also reported adjusted EBITDA of INR 159.6 million in Q1 FY27 compared with INR 147.7 million in Q1 FY26.

Segmental growth points cited in the update

Alongside consolidated financials, the material referenced strong segmental growth rates for the quarter. The segment-level growth rates cited included dental lab revenue up 23.5% year on year, international business up 37.4%, aligner solutions up 28.6%, and pediatric dental up 54.4%.

These growth figures are useful for understanding where traction was strongest in the quarter. They also align with management’s emphasis on “broad-based growth across our dental laboratory and aligner solutions” in the earnings call.

Key numbers at a glance

Segment growth figures mentioned

What management said on the call

Rajesh Khakhar, Chairperson and Whole-Time Director, said in the commentary shared alongside the transcript: “We are pleased to report a strong start to FY27, with Q1 revenue reaching our highest-ever quarterly level of around ₹75.0 crore, representing year-on-year growth of 13.9%.”

In the earnings call narrative, management also said Q1 FY27 was a strong quarter with broad-based growth and improving profitability. EBITDA growth and the margin expansion were linked to product mix, while PAT growth reflected the improved operating performance during the quarter.

Why the transcript matters for investors

For investors tracking quarterly execution, transcripts provide a permanent, searchable record of management’s explanations on what drove the numbers. In this case, the transcript and accompanying disclosure consolidate the company’s key claims: highest-ever quarterly revenue, expanding margins, and notable segment growth rates.

The disclosure also confirms the company’s formal communication to the exchanges about the transcript’s availability, which is relevant for investors who rely on primary-source documents from listed companies.

Conclusion

Laxmi Dental’s Q1 FY27 earnings call transcript, dated August 12, 2026, follows audited results for the quarter ended June 30, 2026 that showed revenue of INR 747.0 million and PAT (after JVs) of INR 103.2 million. The quarter was marked by margin expansion, with EBITDA margin at 19.2% and gross margin at 78.6%. Investors looking for detailed management commentary can refer to the transcript hosted on the company’s investor relations page, as disclosed to BSE and NSE.